Results 221 to 230 of about 91,007 (250)

Role of prostate-specific antigen density after applying age-specific prostate-specific antigen reference ranges

Urology, 1995
To determine the potential role of prostate-specific antigen (PSA) density (PSAD) in the early detection of prostate carcinoma if we apply age-specific PSA reference ranges (2.5 ng/mL or less for ages 40 to 49 years, 3.5 or less for ages 50 to 59, 4.5 or less for ages 60 to 69, and 6.5 or less for ages 70 to 79.We retrospectively reviewed 3234 cases ...
A W, Meshref, M, Bazinet, C, Trudel, S, Aronson, F, Peloquin, M, Nachabe, J, Dessureault, A G, Aprikian, L R, Begin, M M, Elhilali   +9 more
openaire   +2 more sources

Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial [PDF]

Urology, 2002
This prospective, multicenter European Prostate Cancer Detection study evaluated the value and performance of the molecular forms of prostate-specific antigen (PSA) and their derivatives in combination with prostate gland and transition zone volumes in early detection of prostate cancer in patients with PSA levels between 4 and 10 ng/mL.
Djavan, Bob, Remzi, Mesut, Marberger, Michael Johann, Ravery, Vincent, Zlotta, Alexandre, Hammerer, Peter, Reissigl, Andreas, Dobronski, Piotr, Kaisary, Amir   +8 more
openaire   +2 more sources

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer

Prostate Cancer and Prostatic Diseases, 2017
Screening for prostate cancer using prostate-specific antigen (PSA) alone leads to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early evidence on its use for biopsy decisions was conflicting and use of PSA density is not commonly recommended in guidelines.We analyzed biopsy outcomes in 5291 men in the population-based
Tobias Nordström, Olof Akre, Markus Aly, Henrik Grönberg, Martin Eklund   +4 more
openaire   +2 more sources

Prostate-Specific Antigen Density: A Means to Enhance Detection of Prostate Cancer

European Urology, 1994
The ability of serum prostate-specific antigen (PSA) and PSA density (PSAD) to distinguish patients with prostate cancer from those with benign diseases of the prostate was assessed in 495 men. All men were evaluated with PSA determination, digital rectal examination (DRE), transrectal ultrasonography (TRUS) and ultrasound-guided prostatic biopsies ...
J, Ramon, L, Boccon-Gibod, T, Billebaud, L, Astier, M, Kobelinsky, A, Meulemans, M C, Dauge, L, Boccon-Gibod, A, Villers   +8 more
openaire   +2 more sources

Evaluation of patients with diseases of the prostate using prostate‐specific antigen density

British Journal of Urology, 1995
Objective To compare the efficacy of two tests, prostatic‐specific antigen (PSA) and the PSA/prostate volume ratio (PSAD), as diagnostic and staging markers to discriminate patients with benign prostatic hyperplasia (BPH) from patients with cancer of the prostate (CaP).
J M, Wolff, W, Boeckmann, P J, Effert, S, Handt, G, Jakse   +4 more
openaire   +2 more sources

Prostate-specific antigen density: A new prognostic indicator for prostate cancer

International Journal of Radiation Oncology*Biology*Physics, 1993
Prostate specific antigen density, previously described as a ratio of serum prostate specific antigen to the volume of the prostate, has been shown to be an important factor in the discrimination of patients with occult metastatic disease and patients with benign versus malignant prostatic disease.
P G, Zentner, L K, Pao, M C, Benson, D J, McMahon, P B, Schiff   +4 more
openaire   +2 more sources

Prostate-specific antigen density — a reliable parameter for the detection of prostate cancer?

World Journal of Urology, 1996
We compared the prostate-specific antigen density (PSAD) in clinically and surgically staged patients with specimen-confined prostate cancer (n = 57) and in patients with benign hyperplasia (n = 69), who underwent transvesical adenomectomy. The PSAD was calculated from the preoperative PSA level and the specimen volume.
W F, Thon, F, Gadban, M C, Truss, M, Kuczyk, U, Hartmann, U, Jonas   +5 more
openaire   +2 more sources

The Use of Prostate Specific Antigen and Prostate Specific Antigen Density in the Diagnosis of Prostate Cancer in a Community Based Urology Practice

Journal of Urology, 1994
Since 1989 we have used serum prostate specific antigen (PSA) levels as an indication for ultrasound guided systematic biopsies of the prostate. Realizing that the PSA level in part reflects prostatic glandular epithelial volume, we reviewed the accumulated data on our last 2,340 biopsies to determine if the quotient of PSA and prostatic volume ...
F M, Rommel, V E, Agusta, J A, Breslin, H W, Huffnagle, C E, Pohl, P R, Sieber, C A, Stahl   +6 more
openaire   +2 more sources

TRANSITION ZONE PROSTATE SPECIFIC ANTIGEN DENSITY

The Journal of Urology, 1998
Among the new approaches to enhance the performance of prostate specific antigen (PSA) testing in a biopsy population is the use of the free-to-total PSA as well as the transition zone density, which is calculated by dividing the PSA by the transition zone volume.
D W, Lin, M H, Gold, S, Ransom, W J, Ellis, M K, Brawer   +4 more
openaire   +3 more sources

Racial Variations in the Performance of Prostate Specific Antigen and Prostate Specific Antigen Density in the Era of Extended Prostate Biopsy Schemes

Journal of Urology, 2008
The incidence of prostate cancer is known to vary as a function of race. To date few studies have evaluated the performance of the prostate specific antigen test and its indexes in unique racial populations. We examined the performance of prostate specific antigen, prostate specific antigen density and transition zone density in racial groups ...
Christopher S, Elliott, Rajesh, Shinghal, Joseph C, Presti   +2 more
openaire   +2 more sources